A systematic review 1 including 189 studies with a total of 31 150 subjects was abstracted in DARE. Overall survival analysis showed better results of polychemotherapy (PCHT) versus single agent single-agent (CHT) (hazard ratio (HR) 0.82, 95% CI 0.75 to 0.90), CHT with doxorubicin versus CHT with epirubicin (HR 1.13, 95% CI 1.00 to 1.27), CHT versus the same CHT delivered with less intensive schedules (HR 0.90, 95% CI 0.83 to 0.97), endocrine therapy versus the same endocrine therapy at a lower dose (HR 0.86, 95% CI 0.77 to 0.97).
Comment: The quality of evidence is downgraded by inconsistency of results. Quality of life was not reported.
Primary/Secondary Keywords